Identification of Selective Inhibitors for Human Neuraminidase Isoenzymes Using C4,C7-Modified 2‑Deoxy-2,3-didehydro‑N‑acetylneuraminic Acid (DANA) Analogues

• Published in: Journal of medicinal chemistry 2013-04, Vol.56 (7), p.2948-2958
• Main Authors: Zhang, Yi, Albohy, Amgad, Zou, Yao, Smutova, Victoria, Pshezhetsky, Alexey V, Cairo, Christopher W
• Format: Article
• Language: English
• Subjects: Enzyme Inhibitors - chemistry; Enzyme Inhibitors - pharmacology; Humans; Isoenzymes - antagonists & inhibitors; Magnetic Resonance Spectroscopy; Models, Molecular; N-Acetylneuraminic Acid - analogs & derivatives; N-Acetylneuraminic Acid - pharmacology; Neuraminidase - antagonists & inhibitors; Spectrometry, Mass, Electrospray Ionization
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm301892f

In the past two decades, human neuraminidases (human sialidases, hNEUs) have been found to be involved in numerous pathways in biology. The development of selective and potent inhibitors of these enzymes will provide critical tools for glycobiology, help to avoid undesired side effects of antivirals, and may reveal new small-molecule therapeutic targets for human cancers. However, because of the high active site homology of the hNEU isoenzymes, little progress in the design and synthesis of selective inhibitors has been realized. Guided by our previous studies of human NEU3 inhibitors, we designed a series of C4,C7-modified analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) and tested them against the full panel of hNEU isoenzymes (NEU1, NEU2, NEU3, NEU4). We identified inhibitors with up to 38-fold selectivity for NEU3 and 12-fold selectivity for NEU2 over all other isoenzymes. We also identified compounds that targeted NEU2 and NEU3 with similar potency.